Stockscreener 앱 받기
0.45
8.33%
-0.0409
시장 영업 전:
.45
전일 마감가:
$0.4909
열려 있는:
$0.4937
하루 거래량:
1.15M
Relative Volume:
0.32
시가총액:
$17.71M
수익:
-
순이익/손실:
$-27.04M
주가수익비율:
-0.2279
EPS:
-1.9743
순현금흐름:
$-17.53M
1주 성능:
-1.96%
1개월 성능:
+16.19%
6개월 성능:
-81.40%
1년 성능:
-88.28%
1일 변동 폭
$0.45
$0.4943
1주일 범위
$0.3912
$0.5153
52주 변동 폭
$0.37
$8.94
Medicus Pharma Ltd Stock (MDCX) Company Profile
명칭
Medicus Pharma Ltd
전화
610-540-7515
주소
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, AZN, MRK
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
0.45 | 17.71M | 0 | -27.04M | -17.53M | -1.9743 |
LLY
Lilly Eli Co
|
931.09 | 831.80B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
238.41 | 574.24B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
206.37 | 365.02B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
200.81 | 311.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
119.28 | 294.91B | 64.93B | 18.26B | 12.36B | 7.2751 |
Medicus Pharma Ltd 주식(MDCX)의 최신 뉴스
Medicus Pharma on Bloomberg World - thespectrum.com
Medicus Pharma Submits Phase 2 Protocol for Teverelix to FDA - MyChesCo
New to The Street Signs Medicus Pharma Ltd. (NASDAQ:MDCX) to Transformational 12-Part National Media Series Highlighting SkinJect(TM) and Teverelix(R) Platforms - The Olympian
Medicus Pharma Ltd (MDCX) Stock Price, Quote, News & History - Benzinga
Medicus Pharma submits optimized Phase 2 study design for Teverelix - Proactive financial news
Market movers: Virgin Galactic, Soleno Therapeutics, Medicus Pharma... - Proactive financial news
Medicus Pharma Streamlines Phase 2 Teverelix Trial for $2 Billion AUR Market - TipRanks
Medicus Pharma submits optimized Phase 2 Teverelix trial protocol to FDA - Yahoo Finance
Medicus targets recurrent urinary retention with 126-patient study - Stock Titan
EXCLUSIVE: Medicus Pharma Refines Trial Design To Cut Costs, Accelerate Development For Enlarged Prostate - Benzinga
Medicus Pharma submits optimized Phase 2 protocol for Teverelix - grafa.com
Medicus Pharma SkinJect Phase 2 study data endorsed by independent expertICYMI - Proactive financial news
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - gosanangelo.com
Medicus Pharma stock swings after skin cancer treatment results - MSN
Medicus Pharma Ltd. (MDCX) stock price, news, quote and history - Yahoo Finance Singapore
Medicus Pharma clarifies Phase 2 skin cancer study results By Investing.com - Investing.com South Africa
MDCX SEC FilingsMedicus Pharma Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
MDCX Forecast, Price Target & Analyst Ratings | MEDICUS PHARMA LTD (NASDAQ:MDCX) - ChartMill
Medicus Pharma (MDCX) COO granted 50,000 options at $0.50 exercise price - Stock Titan
Director at Medicus Pharma (NASDAQ: MDCX) awarded 25,000 stock options at $0.50 - Stock Titan
Director at Medicus Pharma (NASDAQ: MDCX) receives 25,000 stock options at $0.50 strike - Stock Titan
CMO at Medicus Pharma (MDCX) receives 125,000 stock options grant - Stock Titan
[Form 4] Medicus Pharma Ltd. Insider Trading Activity - Stock Titan
Medicus Pharma (MDCX) director granted stock options for 25,000 Common Shares - Stock Titan
Director Barry Fishman granted 25,000 Medicus Pharma (MDCX) stock options - Stock Titan
Medicus Pharma (MDCX) grants director 25K stock options at $0.50 - Stock Titan
Medicus Pharma (MDCX) Chief Scientific Officer receives 25,000 stock options grant - Stock Titan
Medicus Pharma (MDCX) grants CFO 100,000 stock options - Stock Titan
Medicus Pharma (NASDAQ: MDCX) CEO awarded 325,000 options at $0.50 strike - Stock Titan
Medicus Pharma (NASDAQ: MDCX) director receives grant of 25,000 options at $0.50 strike - Stock Titan
Medicus Pharma eyes registrational study for SkinJect after positive Phase 2 data - Yahoo! Finance Canada
Medicus Pharma Ltd clarifies positive Skinject phase 2 dataset - marketscreener.com
Medicus Pharma Ltd Clarifies Positive Skinject Phase 2 Dataset - tradingview.com
Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset - The Manila Times
Medicus Pharma clarifies Phase 2 skin cancer study results - investing.com
Skin cancer study points to stronger results at higher SkinJect dose - Stock Titan
MDCXW Financials: Income Statement, Balance Sheet & Cash Flow | Medicus Pharma Ltd - Stock Titan
MDCX Stock Price, Quote & Chart | MEDICUS PHARMA LTD (NASDAQ:MDCX) - ChartMill
Ideas Watch: Is Medicus Pharma Ltd Equity Warrant likely to announce a buybackQuarterly Portfolio Summary & Accurate Trade Setup Notifications - baoquankhu1.vn
Small cap wrap: Namibia Critical Metals, Medicus Pharma, Greatland Resources... - Proactive financial news
Medicus Pharma’s SkinJect Phase 2 Data Validated by KOL With 80% Response Rate - TipRanks
Medicus Pharma’s SkinJect Data Earns KOL Validation With 80% Response in Phase 2 - TipRanks
D. Boral Capital cuts Medicus Pharma stock price target on dilution concerns - ca.investing.com
Medicus Pharma highlights independent support for Phase 2 SkinJect results - Yahoo Finance
Medicus Pharma Ltd Reports KOL Validation of Skinject Phase 2 Data of 80% Overall Response Rate - MarketScreener
Medicus Pharma reports Kol validation of Skinject phase 2 data of 80% overall response rate - MarketScreener
Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate - Caledonian Record
[EFFECT] Medicus Pharma Ltd. SEC Filing - Stock Titan
Bull Bear: Is Medicus Pharma Ltd Equity Warrant stock forming a cup and handleMarket Risk Report & Momentum Based Trading Ideas - baoquankhu1.vn
Medicus Pharma Ltd (MDCX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.62%
0.65%
자본화:
|
볼륨(24시간):